Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease

Pharmacotherapy

Volumn 29, Issue 9, 2009, Pages 1061-1072

  Abe, Masanori ^a   Okada, Kazuyoshi ^a   Maruyama, Takashi ^a   Matsumoto, Koichi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chronic kidney disease; CKD; Hydrochlorothiazide; Hypertension; Losartan; Proteinuria

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOOP DIURETIC AGENT; LOSARTAN; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; PATIENT COMPLIANCE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHRONIC DISEASE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY DISEASES; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEINURIA; TREATMENT OUTCOME;

EID: 69249114291     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.9.1061     Document Type: Article

References (40)

1. Marcantoni C, Jafar TH, Oldrizzi L, et al. The role of systemic hypertension in the progression of nondiabetic renal disease. Kidney Int 2000;57:44-48 (Pubitemid 30205439)
2. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int 2001;60:1131-1140 (Pubitemid 34205814)
3. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-1179
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462
5. Brenner BM, Cooper MD, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-869 (Pubitemid 34940825)
6. Weidmann P, Boehlen LM, Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 1993;8:582-584 (Pubitemid 23231138)
7. Lavermann GD, Henning RH, De Jong PE, et al. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001;38:1381-1384
8. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-2572 (Pubitemid 37430158)
9. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for management of hypertension (JSH 2004). Hypertens Res 2006;29:S1-105.
10. Sheinfield GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999;12:80-85
11. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 2006;24:19-27. (Pubitemid 44336815)
12. Cusachs AR, Schmieder RE, Triposkiadis F, et al. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J Hypertens 2008;26:813-818 (Pubitemid 351354931)
13. Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007;11:156-163 (Pubitemid 47012510)
14. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for management of hypertension (JSH 2009). Hypertens Res 2009;32:3-107.
15. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992
16. Gaede P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004;19:2784-2788 (Pubitemid 39480973)
17. Rossing K, Christensen PK, Hovind P, et al. Remission of nephritic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005;11:2241-2247 (Pubitemid 41618913)
18. Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. Hypertens Res 2007;30:325-334 (Pubitemid 46804317)
19. Russo D, Minutolo R, Pasani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25. (Pubitemid 32611753)
20. Iodice C, Balletta M, Minutolo R, et al. Maximal suppression of rennin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int 2003;63:2214-2221 (Pubitemid 36605834)
21. Keilani T, Danesh F, Schlueter W, Molteni A, Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999;33:450-457 (Pubitemid 29107021)
22. Kimura G. Sodium, kidney and circadian rhythm of blood pressure. Clin Exp Nephrol 2001;5:13-18. (Pubitemid 32377863)
23. Nakagawa H, Morikawa Y, Okayama A, et al. Trends in blood pressure and urinary sodium and potassium excretion in Japan: reinvestigation in the 8th year after the intersalt study. J Hum Hypertens 1999;13:735-741 (Pubitemid 29533004)
24. Stamler J, Elliott P, Appel L, et al, for the INTERMAP Research Group. Higher blood pressure in middle-aged American adults with less education: role of multiple dietary factors. The INTERMAP study. J Hum Hypertens 2003;17:655-664 (Pubitemid 37265103)
25. Sacks FM, Svetkey LP, Vollmer WM, et al, for the DASH Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001;344: 3-10.
26. Vogt L, Waanders F, Boomsma F, Zeeuw DD, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008;19:999-1007.
27. Waanders F, Vaidya VS, Goor HV, et al. Effect of reninangiotensin- aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2008;53:16-25.
28. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease - a unifying hypothesis. Hypertension 2001;37:1047-1052
29. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003;92:322-329 (Pubitemid 36258555)
30. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766 (Pubitemid 37093915)
31. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
32. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;363:2022-2031 (Pubitemid 38781102)
33. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type 2 diabetics with hypertension. Hypertens Res 2008;31:7-13. (Pubitemid 351325609)
34. Prisant LM. Fixed low dose combination in first-line treatment of hypertension. J Hypertens 2002;20:S11-19.
35. Mahmud A, Feely J. Low-dose quadruple antihypertensive combination: more efficacious than individual agents - a preliminary report. Hypertension 2007;49:272-275 (Pubitemid 46143001)
36. Shidham G, Hebert LA. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006;47:8-14. (Pubitemid 41828261)
37. Steinhauslin F, Wauters JP. quantitation of proteinuria in kidney transplant patients: accuracy of the urinary protein:creatinine ratio. Clin Nephrol 1995;43:110-115
38. Torng S, Rigatto C, Rush DN, et al. The urine protein-tocreatinine ratio (P/C) as a predictor of 24-hour urine protein excretion in renal transplant patients. Transplantation 2001;72:1453-1456 (Pubitemid 33015775)
39. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renninangiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543-1549 (Pubitemid 350199443)
40. National Kidney Foundation. DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification - guideline 5, assessment of proteinuria. Am J Kidney Dis 2002;39:S93-102.